Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
3181 – 3200
of
3979
Protease Inhibitors
https://clinicalinfo.hiv.gov/guidelines/perinatal/protease-inhibitors
Lopinavir/Ritonavir (Kaletra, LPV/r)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-lopinavir-ritonavir-kaletra
Darunavir (Prezista, DRV)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-darunavir-prezista
Initial Evaluation and Continued Monitoring of HIV During Pregnancy
https://clinicalinfo.hiv.gov/guidelines/perinatal/antepartum-care-initial-evaluation-monitoring-hiv-assessments-during-pregnancy
Appendix C: Antiretroviral Counseling Guide for Health Care Providers
https://clinicalinfo.hiv.gov/guidelines/perinatal/arv-counseling-guide
Appendix B: Invasive Mycoses
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/appendix-b-9
Hepatitis C Virus
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/hepatitis-c-virus
Intrapartum Care for People With HIV
https://clinicalinfo.hiv.gov/guidelines/perinatal/intrapartum-care
Cobicistat (Tybost, COBI)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-pharmacoenhancers-cobicistat-tybost
Ibalizumab
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/ibalizumab
Insulin Resistance, Asymptomatic Hyperglycemia, Diabetes Mellitus
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/insulin-resistance-asymptomatic-hyperglycemia-diabetes-mellitus
Overview
https://clinicalinfo.hiv.gov/guidelines/perinatal/prepregnancy-counseling-childbearing-age-overview
Integrase Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-arv/integrase-inhibitors
Pneumocystis jirovecii Pneumonia
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/pneumocycstis-jirovecii-pneumonia
Efavirenz
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/efavirenz
Appendix B: Cryptosporidiosis/ Microsporidiosis
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cryptosporidiosis-microsporidiosis
Central Nervous System Toxicity
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/cns-toxicity
Nelfinavir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/nelfinavir
Bartonellosis
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/bartonellosis
Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/treatment-hiv-associated
Pagination
First page
«
Previous page
‹
…
Page
156
Page
157
Page
158
Page
159
Current page
160
Page
161
Page
162
Page
163
Page
164
…
Next page
›
Last page
»